Search
+
    Invest with Confidence. Lead with Insights.
    • Drench in the knowledge with exclusive insights, ePaper & smart market tools with ETPrime.

    Comeback and re-rating supported by numbers? 5 pharma stocks with upside potential of up to 21%

    Synopsis

    Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant changes over the past decade. Marking a transition from a period of consolidation and valuation readjustment to one where the focus has shifted towards more sustainable and compliant operational practices. This transformation highlights a shift in the strategic approach adopted by pharmaceutical companies. Historically, the expansion strategies of many pharma companies were driven by optimistic powerpoint presentations forecasting market growth. However, this approach often overlooked the critical aspect of regulatory compliance, leading to various challenges. Over the years the Indian pharmaceutical industry has understood that regulatory compliance might be slightly more time consuming and also expensive but in long run it pays both for the real business growth and improving valuations. Will the industry remember the critical lesson is key.

    After the IT sector, pharma is another sector where India enjoys inherent advantages similar to those in the IT sector, a skilled yet cost-effective workforce and lower manufacturing costs. This is what led to the Indian pharma sector getting onto a new journey in the mid 90’s of positioning India as a competitive player in the global market, especially in the production and export of generic drugs. A significant strategic pivot was done by many
    • FONT SIZE
    • SAVE
    • PRINT
    • COMMENT
    ET

    Uh-oh! This is an exclusive story available for selected readers only.

    Worry not. You’re just a step away.

    Why ?

    • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

    • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

    • Clean experience with
      Minimal Ads
    • Comment & Engage with ET Prime community
    • Exclusive invites to Virtual Events with Industry Leaders
    • A trusted team of Journalists & Analysts who can best filter signal from noise
    • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

    The Economic Times